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ABSTRACT: EHD1 mediates long-loop recycling of
many receptors by forming signaling complexes using its
EH domain. We report the design and optimization of
cyclic peptides as ligands for the EH domain of EHD1. We
demonstrate that the improved affinity from cyclization
allows fluorescence-based screening applications for EH
domain inhibitors. The cyclic peptide is also unusually
well-structured in aqueous solution, as demonstrated using
nuclear magnetic resonance-based structural models.
Because few EH domain inhibitors have been described,
these more potent inhibitors will improve our under-
standing of the roles of EHD1 in the context of cancer
invasion and metastasis.
The dysregulation of endocytosis and vesicle trafficking is acharacteristic feature of many cancers, particularly during
the poorly understood processes of invasion and metastasis.1
Critical receptors responsible for cell signaling, cell−cell
interactions, and cell−matrix interactions all require endocy-
tosis and recycling pathways for their roles in malignant growth.
For example, an increase in the long-loop recycling of β1-
integrins is observed in motile cancer cells, assisting polar-
ization and invasion.1,2 Thus, the proteins involved in the long-
loop recycling pathway are potential anti-invasiveness cancer
targets. While some chemical tools for modulating vesicle
trafficking are available, no specific inhibitors of long-loop
recycling have been discovered to date.3−5 EH domain-
containing protein 1 (EHD1) has emerged as a critical
regulator of long-loop endocytic recycling. Genetic knockdown
of EHD1 prevents recycling of β1-integrin, and misregulation
and mutation of EHD1 have been implicated in cancer
progression.6,7
EHD1 binds several key proteins involved in vesicle
trafficking, many via its EH domain. Proteins with C-terminal
EH domains, such as EHD1, are primarily involved in
intracellular vesicular transport, while proteins with N-terminal
EH domains, such as Eps15, are more involved in
endocytosis.6,8 These two functional classes of EH domains
also have different substrate preferences, but all EH domains
recognize a core asparagine-proline-phenylalanine (NPF) motif.
Nuclear magnetic resonance (NMR) structures of NPF-
containing peptides bound to EH domains, including the EH
domain of EHD1, have revealed that the NPF motif forms a
type 1 β-turn when bound.9−11
Previous attempts to identify binding partners of EH
domains have used yeast two-hybrid screens, phage-display
selections, and pull-down assays.12−15 However, all identified
inhibitors to date are linear peptides with low affinities. Using
isothermal titration calorimetry (ITC), we measured the affinity
(Kd) of a typical linear peptide ligand to be 35.7 ± 3.7 μM at 20
°C and a physiological salt concentration (Table S2 of the
Supporting Information). To date, quantitative determination
of peptide−EH domain affinities relied on NMR and ITC,
which are robust but demanding assays, and typically required
low-salt or no-salt conditions to increase affinity (Table S2 of
the Supporting Information). Without higher-affinity inhibitors,
practical assays with higher throughput and a low level of
reagent consumption (such as fluorescence polarization) have
not been feasible.
Earlier work with linear peptides established that C-terminal
type EH domains prefer multiple negatively charged residues
directly C-terminal to the NPF motif.16,17 Thus, we
incorporated the sequence NPFEE within a head-to-tail cyclic
peptide, with the hypothesis that cyclization would stabilize the
β-turn and preorganize the binding epitope.17 A tyrosine was
also included N-terminal to the NPF sequence because it is
present in endogenous EHD1-EH ligands and allowed for
spectrophotometric determination of the ligand concentration.
For direct comparison to prior work in this area, we first
analyzed ligand binding to EHD1-EH by ITC with no NaCl
and then repeated the experiments at 15 and 150 mM NaCl
(Table S2 and Figure S3 of the Supporting Information). At
physiological NaCl concentrations, cyclic peptide cNPF1 had a
Kd of 9.9 ± 0.8 μM. The nearly 4-fold improvement in affinity
was consistent at all salt conditions. This suggested that the
increase in affinity was not due to electrostatic interactions, but
rather the conformation of the NPF motif. These data indicated
that the NPF motif and flanking residues were able to make
more favorable contacts with EHD1-EH within the context of a
cyclic scaffold.
While ITC is powerful, we sought a more rapid and
convenient assay for discovering EHD1-EH inhibitors. To this
end, we linked cNPF1 to fluorescein (cNPF1Flu) to monitor
direct EHD1-EH binding using fluorescence polarization (FP).
We also synthesized dye-labeled cNPF1 analogues with an
altered ring size (cNPF2Flu and cNPF3Flu), cNPF1 analogues
with a reduced overall negative charge (cNPF4Flu and
cNPF5Flu), and linear and non-NPF-containing controls
(sequences listed in Table 1). FP assays were performed at
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15 and 150 mM NaCl (Figure 1a, Figure S4 of the Supporting
Information, and Table 1). At 15 mM NaCl, the data fit well to
a two-state binding curve. Reduced affinities were observed at
150 mM NaCl, but these data were fit well by assuming upper
bounds for polarization similar to those observed at 15 mM
(Figure S4 of the Supporting Information). The FP assay
produced Kd values similar to those obtained by ITC, with very
similar trends among linear and cyclic peptides, and among
different salt concentrations. We concluded that this FP assay
was reliable for assessing binding to EHD1-EH. We also
showed that increasing the ring size (cNPF2Flu) or decreasing
the ring size (cNPF3Flu) within cNPF1Flu led to poorer binding.
This is consistent with the hypothesis that a specific cyclic
structure improves binding of the NPFEE sequence to EHD1-
EH.
To rule out the possibility that nonspecific electrostatics
dominates cNPF1 binding, we tested a cyclic peptide that
maintained the negative charge but lacked the critical NPF
motif (cAPAFlu). No binding was observed up to 67 μM EHD1-
EH even at 15 mM NaCl, demonstrating that an intact NPF
motif is the primary requirement for binding. Next, we probed
the effects of reducing the number of charged residues in the
context of a cyclic peptide with cNPF4Flu, cNPF5Flu, and
cNPF6Flu. All three of these inhibitors had less affinity for
EHD1-EH, which demonstrated that negatively charged
flanking sequences boost affinity for cyclic ligands, as they do
for linear ligands.16,17 Interestingly, cNPF5Flu exhibited an only
3-fold loss of affinity. This implies that EHD1-EH ligands with
moderate affinity and reduced negative charge can be further
designed and optimized, either as a free acid or in an esterified
form, for later cellular studies.
To evaluate the selectivity of our probes for EHD1-EH over
unrelated EH domains, we expressed and purified the second
EH domain of Eps15 (Eps15-EH2) and used circular dichroism
spectroscopy to verify that it was properly folded (Figure S5b
of the Supporting Information).16 Under low-salt conditions,
the dye-labeled probes were unable to bind this EH domain up
to an Eps15-EH2 concentration of 50 μM (Figure S4d of the
Supporting Information). This provided initial evidence that
these probes are selective for the C-terminal type of EH
domain (EHD1-EH) over the N-terminal type of EH domain
(Eps15-EH2).
To develop an assay suitable for high-throughput screening
applications, we used cNPF1Flu to set up a FP competitive
binding assay. The probe was used with a range of inhibitors to
establish its effectiveness for future screens (Figure 1b and
Table 2). As with the direct binding assays, cNPF1 was the
strongest inhibitor. An analogue of cNPF1Flu with an acetyl
group in place of the dye was also tested and showed 2-fold less
potent inhibition (Table 2). This suggests that the introduction
of the dye decreases the cNPF1 affinity and that its positioning
within the cNPF1 ring could be further optimized. cNPF4 was
tested as an example of a lower-affinity inhibitor, and cAPA was
used as a negative control. Because the results showed the same
trends observed in direct binding assays, we concluded that this
competitive binding assay represents a useful assay for high-
throughput screening for EH domain inhibitors.
As a complement to screening, we also sought a basis for the
structure-based design of additional macrocyclic EH domain
inhibitors. We determined the solution structures of the linear
NPF-containing peptide and the cyclic peptide cNPF1 (Figure
2). The linear peptide was relatively unstructured in aqueous
solution (Figure 2a), though some low-energy conformations
showed the characteristic β-turn. cNPF1, by contrast, adopted a
tight ensemble of well-structured conformations in aqueous
solution (Figure 2b). This is unusual for a cyclic octamer, and
the surprising degree of structure is likely promoted by the
turn-forming NPF sequence. The NPF motif of cNPF1 formed
a β-turn in solution that was nearly identical to the turn
observed in linear NPF motifs bound to EHD1-EH.17 When
superimposed with the NPF motif within a previously
determined NPF/EHD1-EH structure, the backbone of
cNPF1 overlaid with the NPFE sequence of the ligand with a
root-mean-square deviation of 0.333 Å (Figure 2c). A posed
model of cNPF1 within the binding site of EHD1-EH (Figure
2d) provides a clear rationale for the observed structure−
activity relationships within cNPF1 analogues and provides an
excellent starting point for the structure-based design of
additional cyclic peptide and small-molecule macrocycle
inhibitors of EHD1-EH.17
There are relatively few chemical agents that can be used to
study vesicle trafficking, and even molecules with relatively high
IC50 values are welcomed as useful tools. For example, the small
molecule dynasore, first reported in 2006, has an IC50 of ∼15
Table 1. Binding of Dye-Labeled Probes to EHD1-EH
peptide sequence Kd (μM)
a low-salt Kd (μM)
b
LinFlu Flu-ββYNPFEE-NH2 31.4 ± 0.5 6.9 ± 0.6
cNPF1Flu -YNPFEEGK(Flu)- 16.8 ± 0.1 3.3 ± 0.3
cNPF2Flu -YNPFEEγK(Flu)- 20.5 ± 0.3 4.5 ± 0.3
cNPF3Flu -YNPFEEK(Flu)- 57.8 ± 0.2 11.3 ± 1.0
cNPF4Flu -YNPFAEGK(Flu)- 46.7 ± 0.9 17.4 ± 0.1
cNPF5Flu -YNPFEAGK(Flu)- 28.3 ± 0.3 8.7 ± 0.9
cNPF6Flu -YNPFEQGK(Flu)- 34.0 ± 0.3 12.8 ± 0.8
cAPAFlu -YAPAEEGK(Flu)- ndc >67
aKd at 150 mM NaCl.
bKd at 15 mM NaCl.
cNot determined.
Figure 1. (a) Direct binding assay of each probe with EHD1-EH.
Curve fits match the Kd values reported in Table 1. (b) Competitive
binding assay with cNPF1Flu. Curve fits match the IC50 values reported
in Table 2. Error bars show the standard deviation from three or more
independent trials. Experiments were performed in 25 mM MOPS
(pH 6.8), 1 mM CaCl2, and 15 mM NaCl with 1.5% DMSO and 0.1%
Tween 20.
Table 2. Competition Assay for EHD1-EH Binding
peptide sequence IC50 (μM)
linear Ac‑YNPFEEGG-NH2 107 ± 1
cNPF1 -YNPFEEGG- 49.2 ± 0.2
cNPF1B -YNPFEEGK(Ac)- 100 ± 1
cNPF4 -YNPFAEGG- 240 ± 1
cAPA -YAPAEEGG- >450
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μM in a biochemical assay of dynamin GTPase activity.18 It is
widely used to study clathrin-dependent endocytosis despite
the fact that it is typically applied at a concentration of 80
μM.19 By this standard, cNPF1 and related molecules have
potential as chemical biology tools, pending further work to
maximize target affinity and cell penetration. The 4-fold
improvement in affinity for cNPF1 over those of linear
peptides also allowed the development of a straightforward
fluorescence polarization competition assay. This assay is high-
throughput-ready and will accelerate the development of
additional classes of constrained peptides as inhibitors, as well
as small-molecule inhibitors that target the same pocket. These
approaches will increase the likelihood that the overall effort
produces cell-penetrant, reasonably potent antagonists of EH
domain-dependent vesicle trafficking pathways. Ultimately,
cNPF1 and related EHD1 inhibitors will allow pharmacological
investigation of EHD1’s roles in vesicle trafficking and its
importance in cancer invasion and metastasis.
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Figure 2. (a) Thirty lowest-energy structures calculated for the linear
NPF-containing peptide (Ac-YNPFEEGG-NH2 sequence) in aqueous
solution. The NPF motif is colored green, and other residues are
colored magenta. (b) Thirty lowest-energy structures calculated for
cNPF1 in aqueous solution. The NPF motif is colored green, and
other residues are colored cyan. (c) Overlay of cNPF1 with the
structure of the YNPFEE sequence from a peptide bound to EHD1-
EH. The backbone overlay for the residues NPFE has a root-mean-
square deviation of 0.333 Å. cNPF1 is colored as in panel b, and
YNPFEE is colored gray. (d) Solution structure of cNPF1 positioned
in the binding pocket of EHD1-EH. cNPF1 is colored as in panel b,
and EHD1-EH is shown as a surface colored according to
electrostatics.
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